1740-88-1

Basic information

• Product Name: 5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole
• Synonyms: 5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole;5-Bromo-2-chloromethyl-1H-benzoimidazole;1H-BenziMidazole, 6-broMo-2-(chloroMethyl)-;6-Bromo-2-chloromethyl-1H-benzoimidazole;5-Bromo-2-(chloromethyl)-1h-benzimidazole
• CAS NO: 1740-88-1
• Molecular Formula: C₈H₆BrClN₂
• Molecular Weight: 245.51
• Mol File: 1740-88-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 426.1 °C at 760 mmHg
• Flash Point: 211.5 °C
• Appearance: /
• Density: 1.766 g/cm³
• CAS DataBase Reference: 5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole(1740-88-1)
• EPA Substance Registry System: 5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole(1740-88-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1740-88-1(Hazardous Substances Data)

Usage

General Description

5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole is a chemical compound with the molecular formula C9H6BrClN2. It is a heterocyclic organic compound that contains both bromine and chlorine atoms. 5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole has potential applications in medicinal chemistry and pharmaceutical research, particularly in the development of new drugs and therapeutic agents. Its unique structure and reactivity make it a valuable building block for the synthesis of complex organic molecules. Additionally, 5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole may also have use in other fields such as materials science and agrochemicals. Its diverse potential applications make it an important target for further study and development.

Upstream product

• 79-11-8 chloroacetic acid 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 540516-28-7 (5-bromo-1H-benzo[d]imidazol-2-yl)methanol 
• 36743-66-5 ethyl chloroacetimidate hydrochloride 

Downstream Products

• 956283-22-0 (5-bromo-1H-benzimidazol-2-ylmethyl)-triphenyl-phosphonium chloride 
• 1225045-55-5 N-[(5-bromo-1H-benzimidazol-2-yl)methyl]-2-chloroaniline 
• 1178363-80-8 N-[(5-bromo-1H-benzimidazol-2-yl)methyl]-3-chloroaniline 
• 1183502-57-9 N-[(5-bromo-1H-benzimidazol-2-yl)methyl]aniline 
• 1225045-57-7 N-[(5-bromo-1H-benzimidazol-2-yl)methyl]-4-methoxyaniline 
• 1183314-68-2 N-[(5-bromo-1H-benzimidazol-2-yl)methyl]-4-methylaniline 
• 1033624-86-0 5-bromo-2-(4-trifluoromethyl-phenoxymethyl)-1H-benzoimidazole 

Relevant articles and documents

INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Synthesis and evaluation of selected benzimidazole derivatives as potential antimicrobial agents

A library of 53 benzimidazole derivatives, with substituents at positions 1, 2 and 5, were synthesized and screened against a series of reference strains of bacteria and fungi of medical relevance. The SAR analyses of the most promising results showed that the antimicrobial activity of the compounds depended on the substituents attached to the bicyclic heterocycle. In particular, some compounds displayed antibacterial activity against two methicillin-resistant Staphylococcus aureus (MRSA) strains with minimum inhibitory concentrations (MICs) comparable to the widely-used drug ciprofloxacin. The compounds have some common features; three possess 5-halo substituents; two are derivatives of (S)-2-ethanaminebenzimidazole; and the others are derivatives of one 2-(chloromethyl)-1Hbenzo[ d]imidazole and (1H-benzo[d]imidazol-2-yl)methanethiol. The results from the antifungal screening were also very interesting: 23 compounds exhibited potent fungicidal activity against the selected fungal strains. They displayed equivalent or greater potency in their MIC values than amphotericin B. The 5-halobenzimidazole derivatives could be considered promising broad-spectrum antimicrobial candidates that deserve further study for potential therapeutic applications.

Benzimidazole Modulators of VR1

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.